NT-proBNP指导的急性失代偿性心衰治疗:PRIMA II随机对照试验
PRIMA II研究纳入NT-proBNP>1700 ng/L的急性失代偿性心衰患者405例,随机比较院内NT-proBNP相对目标(出院时较入院降低>30%)指导治疗与常规治疗。结果显示指导组更多患者达到NT-proBNP降低>30%(80% vs 64%,P=0.001),但180天全因死亡和心衰再入院复合终点(HR 0.96,95%CI 0.72-1.37,P=0.99)及院外存活天数(中位178 vs 179天,P=0.39)均无显著改善,次要终点亦无差异。
要点
- NT-proBNP指导治疗未改善180天全因死亡和心衰再入院复合终点。
- 指导组更多患者达到NT-proBNP降低>30%(80% vs 64%,P=0.001)。
- 180天院外存活天数中位数两组无显著差异(178 vs 179天,P=0.39)。
核心结论
- 在临床稳定后以NT-proBNP降低>30%为目标的治疗指导未改善6个月结局。
研究设计与样本
- 前瞻性随机对照试验,405例NT-proBNP>1700 ng/L的急性失代偿性心衰患者,临床稳定后1:1随机分为NT-proBNP指导组和常规治疗组。
主要发现
- NT-proBNP指导组出院时NT-proBNP降低>30%的患者比例显著高于常规组(80% vs 64%,P=0.001)。
- 180天全因死亡和心衰再入院复合终点无显著改善(HR 0.96,95%CI 0.72-1.37,P=0.99)。
- 180天院外存活天数中位数两组无显著差异(178 vs 179天,P=0.39)。
- 次要终点(180天全因死亡、180天心衰再入院、90天复合终点)均无显著改善。
关键数值与推荐
- 入选标准:急性失代偿性心衰且NT-proBNP>1700 ng/L。
- NT-proBNP指导目标:出院时较入院降低>30%。
临床怎么用
- 院内以NT-proBNP相对降低>30%为目标指导治疗虽更易达标,但未转化为6个月临床获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The concept of natriuretic peptide guidance has been extensively studied in patients with chronic heart failure (HF), with only limited success. The effect of NT-proBNP (N-terminal probrain natriuretic peptide)-guided therapy in patients with acute decompensated HF using a relative NT-proBNP target has not been investigated. This study aimed to assess whether NT-proBNP-guided therapy of patients with acute decompensated HF using a relative NT-proBNP target would lead to improved outcomes compared with conventional therapy. METHODS: We conducted a prospective randomized controlled trial to study the impact of in-hospital guidance for acute decompensated HF treatment by a predefined NT-proBNP target (>30% reduction from admission to discharge) versus conventional treatment. Patients with acute decompensated HF with NT-proBNP levels >1700 ng/L were eligible. After achieving clinical stability, 405 patients were randomized to either NT-proBNP-guided or conventional treatment (1:1). The primary end point was dual: a composite of all-cause mortality and HF readmissions in 180 days and the number of days alive out of the hospital in 180 days. Secondary end points were all-cause mortality within 180 days, HF readmissions within 180 days, and a composite of all-cause mortality and HF readmissions within 90 days. RESULTS: Significantly more patients in the NT-proBNP-guided therapy group were discharged with an NT-proBNP reduction of >30% (80% versus 64%, P=0.001). Nonetheless, NT-proBNP-guided therapy did not significantly improve the combined event rate for all-cause mortality and HF readmissions (hazard ratio, 0.96; 95% confidence interval, 0.72-1.37; P=0.99) or the median number of days alive outside of the hospital (178 versus 179 days for NT-proBNP versus conventional patients, P=0.39). Guided therapy also did not significantly improve any of the secondary end points. CONCLUSIONS: The PRIMA II trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?) demonstrates that the guidance of HF therapy to reach an NT-proBNP reduction of >30% after clinical stabilization did not improve 6-month outcomes. CLINICAL TRIAL REGISTRATION: URL: http://www.trialregister.nl. Unique identifier: NTR3279.
引用
- Stienen S, Salah K, Moons AH, et al. NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-Guided Therapy in Acute Decompensated Heart Failure: PRIMA II Randomized Controlled Trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?). Circulation. 2017. PMID: 29242350. doi:10.1161/CIRCULATIONAHA.117.029882
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。